Trending Up0.0195 (1.0260%)
  • Bid / Lots
    1.7000/ 1
  • Ask / Lots
    2.4500/ 1
  • Open / Previous Close
    1.8600 / 1.9005
  • Day Range
    Low 1.5500
    High 1.9700
  • 52 Week Range
    Low 1.3401
    High 4.0000
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.9005
09:32 ET4181.86
09:34 ET59471.56
09:36 ET12001.7
09:48 ET4001.82
10:06 ET1001.9
10:08 ET2001.85
10:12 ET6001.86
10:28 ET8911.89
10:57 ET1001.93
11:42 ET1401.92
11:47 ET1001.89
11:51 ET1001.89
12:00 ET6001.9
12:05 ET1001.94
12:09 ET1001.94
12:16 ET1401.945
12:18 ET1101.945
12:25 ET10001.95
12:27 ET1301.945
12:34 ET1001.95
12:41 ET4901.945
12:43 ET1101.945
01:01 ET1001.97
01:12 ET1001.97
01:32 ET7581.95
01:33 ET10181.95
01:39 ET1001.965
01:51 ET3001.945
01:53 ET4001.945
01:55 ET4001.94
02:02 ET2001.94
02:04 ET1001.94
02:11 ET2001.94
02:22 ET1001.94
02:24 ET1001.94
02:31 ET1001.94
02:33 ET1001.94
02:36 ET1001.94
02:42 ET1001.94
02:44 ET1001.94
02:45 ET1001.94
02:51 ET2001.94
02:54 ET1001.94
02:56 ET1001.94
03:02 ET1001.94
03:03 ET1001.94
03:12 ET1001.935
03:14 ET2001.97
03:21 ET1001.93
03:23 ET1001.93
03:32 ET1001.93
03:34 ET1001.93
03:41 ET1001.925
03:43 ET6001.92
03:52 ET1001.9175
03:54 ET1001.925
03:56 ET2001.925
03:59 ET2001.92
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRZLT
Rezolute Inc
United StatesADVM
Adverum Biotechnologies Inc
United StatesPVCT
Provectus Biopharmaceuticals Inc
United StatesBDTX
Black Diamond Therapeutics Inc
United StatesRLMD
Relmada Therapeutics Inc
United StatesMYMD
MyMD Pharmaceuticals Inc
As of 2023-04-01

Company Information

Rezolute, Inc. (Rezolute) is a clinical-stage biopharmaceutical company, which is engaged in developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. The antibody modifies insulin’s binding and signaling to maintain glucose levels in a normal range, which counteracts the effects of elevated insulin in the body. It is a potential treatment for congenital hyperinsulinism (HI), which is an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase II. The Company is also developing RZ402, an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME) in Phase I.

Contact Information

201 Redwood Shores Pkwy Ste 315REDWOOD CITY, CA, United States 94065-1134


Chairman of the Board
Young-Jin Kim
Chief Executive Officer, Principal Financial Officer, Director
Nevan Elam
Co-Founder, Scientist Emeritus
Sankaram Mantripragada
Chief Medical Officer
Brian Roberts
Independent Director
Philippe Fauchet

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.